485results about "Serum immunoglobulins" patented technology

The invention relates to the technical field of biological medicines, and particularly discloses an anti-human CD3 rabbit recombinant monoclonal antibody as well as a preparation method and application thereof. The antibody obtains anti-CD3 immune response by immunizing a rabbit, is obtained by combining single B cell sorting, gene cloning and a mammalian cell expression system, and has high affinity and good specificity. The antibody can effectively recognize CD3 positive T cells in human peripheral blood and can be applied to the fields of flow cytometry, immunohistochemistry, T cell function research and the like. Experimental results show that the antibody has the advantages of high titer, strong fluorescence signal, low background and the like, and is superior to the traditional murine anti-CD3 antibody. Amino acid sequences of light chain and heavy chain variable regions of the antibody are further obtained, and controllability and repeatability of antibody expression are achieved. The antibody has important scientific research value and industrial application prospect, and is suitable for various scenes such as T cell marker detection, immune state evaluation, immunotherapy auxiliary research and the like.

The invention provides preparation of an anti-p-Tau217 antibody and application of the anti-p-Tau217 antibody in an Alzheimer's disease detection kit, and belongs to the technical field of antibodies and immunodetection, the anti-p-Tau217 antibody comprises a heavy chain variable region and a light chain variable region, a coding gene of the heavy chain variable region comprises a nucleotide sequence shown in SEQ ID NO.1, and a coding gene of the light chain variable region comprises a nucleotide sequence shown in SEQ ID NO.2. The coding gene of the light chain variable region comprises a nucleotide sequence shown in SEQIDNO.3, the heavy chain variable region comprises an amino acid sequence shown in SEQIDNO.2, and the light chain variable region comprises an amino acid sequence shown in SEQIDNO.3. The invention also discloses a preparation method. The invention provides preparation of an anti-p-Tau217 antibody and application of the anti-p-Tau217 antibody in an Alzheimer's disease detection kit. The successful expression of the monoclonal anti-p-Tau217 antibody with high affinity is realized, and the monoclonal anti-p-Tau217 antibody is used for detecting the Alzheimer's disease.

The invention relates to genetically encoded fusion proteins comprised of a capture component that binds a target with high affinity and a peptide polymer, such as elastin-like polypeptides, that display phase behavior and can be used for purification. The invention further relates to methods for optimizing capture fusion proteins for individual biologic targets such that phase separation occurs under desirable conditions, such as at room temperature, lower concentrations of salt, and / or at suitable pH ranges and optimized capture domains and polypeptides with phase behavior that have been identified by the optimization methods.

The present invention provide novel immunofiber compositions for protein or peptide purification and simple and cost-efficient methods and systems using these compositions. In some embodiments, the immunofibers comprise a customized Z-33 peptide derived from Staphylococcus aureus Protein A which is used to construct immuno-amphiphile molecules that assemble into immunofibers in aqueous solution with bioactive epitopes on the surface and have peptide or protein binding ability.

The invention provides bovine ephemeral fever virus positive serum as well as a preparation method and application thereof. The preparation method comprises the following steps: culturing bovine ephemeral fever virus by using MDBK suspension cells, inactivating by using beta-propiolactone, concentrating by using a 500kd hollow fiber column to obtain an antigen solution, and emulsifying the antigen solution and 61VG adjuvant according to a mass ratio of 1: 1.5 to prepare the vaccine; carrying out primary immunization and secondary immunization on the receptor, collecting blood of which the serum neutralizing antibody titer is greater than 1: 4096 14-21 days after the secondary immunization, and separating to obtain positive serum. The positive serum can be used for specific test, identification test and the like of the bovine ephemeral fever virus, can also be used for preparing related reagents, kits and standard substances, and provides efficient and normative technical support for prevention and control of bovine ephemeral fever.

The invention discloses prokaryotic expression and purification of Echinococcus multilocularis glutathione S-transferase, and preparation and application of a polyclonal antibody, and relates to the technical field of biology.The technical key point is that the preparation method of the polyclonal antibody of the Echinococcus multilocularis glutathione S-transferase comprises the following steps that S1, RNA in vesicle tissue of Echinococcus multilocularis is extracted, and cDNA is prepared; s2, carrying out PCR (Polymerase Chain Reaction) amplification by taking the cDNA as a template to obtain an EmGST gene which can encode an amino acid sequence as shown in SEQ ID NO: 1; s3, connecting the EmGST gene to a prokaryotic expression vector plasmid through a double digestion enzyme reaction to construct a recombinant vector, then transfecting the recombinant vector to competent escherichia coli, and inducing prokaryotic expression and purification to obtain a recombinant protein; and S4, immunizing a mouse to prepare antiserum by taking the echinococcosis multilocularis glutathione transferase as an antigen, and purifying the antiserum to obtain the polyclonal antibody of the echinococcosis multilocularis glutathione transferase. The ImGST protein polyclonal antibody prepared by the invention has the advantages of high titer and good specificity.

The invention belongs to the field of antibody development, and discloses a screening method and application of a human-mouse protein high homologous target antibody based on a fully humanized antibody mouse. Aiming at the problem of weak antibody response caused by immune tolerance of human-mouse high homologous targets (protein homology is greater than or equal to 95%), the following scheme is provided: in embryonic stem cells (ES cells) of HUGO-Mabfully humanized antibody transgenic mice, a mouse target gene (such as ACVR2A) is knocked out through a Turbo Knockout technology, and homozygous knockout ES clones are screened; carrying out microinjection on the clones to the whitened B6 mouse blastocyst, and transplanting a pregnant mouse to obtain a Founder mouse; the Founder mouse is subjected to target antigen immunization for more than or equal to 4 times (the Freund's complete adjuvant is used for the first time), and the titer of the serum antibody is detected. According to the invention, 100% homozygous knockout chimeric efficiency is realized in the Founder stage, the mouse construction period is shortened from traditional 8-10 months to 3-4 months, and the diversity and affinity of the antibody are significantly improved (titer reaches 1: 729,000). The obtained antibody can be used for preparing medicines for treating tumors or autoimmune diseases.

The present disclosure provides a process for concentrating proteins including an ultrafiltering, a diafiltering, and a second ultrafiltering sequence, at elevated temperatures, such as above about 30° C. The disclosure also includes a process for preparing highly concentrated antibody compositions, and highly concentrated antibody products.

Pharmaceutical formulations comprising an antibody that specifically binds to human interleukin-4 receptor alpha (hIL-4Rα) are provided. The formulations may contain, in addition to an anti-IL-4Rα antibody, one or more buffers, at least one amino acid, at least one sugar, and a surfactant. Methods for producing pharmaceutical formulations with reduced lipase activity are also provided, which may include subjecting a drug substance to agitation stress, heat stress, and additional ion exchange or size exclusion chromatography. In one aspect, the pharmaceutical formulations do not have appreciable subvisible particle formation in the presence of lipase, and exhibit a substantial degree of antibody stability during storage and after being subjected to thermal and other physical stresses.

The invention discloses an influenza C virus HEF protein polyclonal antibody preparation method, which comprises: carrying out signal peptide prediction, antigen epitope screening and hydrophobicity analysis through bioinformatics, constructing a recombinant prokaryotic expression vector pET32a-HEF by using a seamless cloning technology, and efficiently expressing the HEF protein in Escherichia coli to obtain the influenza C virus HEF protein polyclonal antibody. The inclusion body protein yield is improved by optimizing conditions; and purifying by nickel column affinity chromatography to obtain high-purity recombinant protein, emulsifying the high-purity recombinant protein and a Freund's adjuvant, immunizing a Japanese white rabbit, immunizing for three times, and collecting high-titer serum. The method breaks through detection limitation caused by antigen tag concealment in a eukaryotic expression system, the obtained polyclonal antibody is high in specificity, the eukaryotic expression HEF protein can be accurately recognized, and a key tool is provided for ICV virus-like particle identification, vaccine research and development and diagnosis technologies. Compared with a traditional method, the scheme is simple and convenient to operate, low in cost and high in antibody titer, and has remarkable application value.

The invention belongs to the technical field of biology, and particularly relates to a human metapneumovirus mouse adapted strain and application thereof. Compared with a wild strain, the strain has higher susceptibility to animals; the strain can be used for treating BALB / c mice and can cause typical clinical symptoms and even death, for example, after the strain infects the BALB / c mice, the disease symptoms are obvious, the weight of 83% infected mice is severely reduced to 75% or below and reaches the humanity killing standard, and the death rate reaches 50% or above 4 days after the strain infects the BALB / c mice; the strain can be used for constructing a cell model or an animal model of human metapneumovirus infection or diseases caused by the human metapneumovirus infection, and is further used for screening drugs for preventing and / or treating the human metapneumovirus infection or the diseases caused by the human metapneumovirus infection. In addition, the strain can also be used for preparing medicines for preventing and / or treating human metapneumovirus infection or diseases caused by the human metapneumovirus infection, preparing antibodies or antiserum for resisting the human metapneumovirus and the like.

The invention discloses a polyclonal antibody of a grouper iridovirus SGIV VP101 gene and application of the polyclonal antibody. The polyclonal antibody is prepared from an SGIVVP101 gene, and the nucleotide sequence of the VP101 gene of an optimized codon is as shown in SEQ ID NO. 1. The polyclonal antibody of the SGIV VP101 gene recombinant expression protein prepared by the invention has good specificity, not only can specifically recognize a prokaryotic expression product of the SGIV VP101, but also can be used for quantitative and positioning analysis of the SGIV VP101 in vivo and in vitro. The successful preparation of the polyclonal antibody of the recombinant expression protein of the SGIV VP101 gene lays a foundation for the establishment of an SGIV immunological detection method, the quantitative and positioning analysis of the protein of the VP101 gene and the analysis of gene functions.

The invention discloses an allergen specific IgE and IgG antibody composite quality control product or calibration product as well as a preparation method and application thereof, and belongs to the technical field of biological detection. The preparation method comprises the following steps: obtaining a whole-genome sequence comprising a human IgE constant region gene sequence, a human IgG4 constant region gene sequence and a human IgG1 constant region gene sequence, and preparing a fusion protein simultaneously containing a human IgE Fc segment and a human IgG Fc segment; immunizing a healthy animal by using the allergen to obtain a purified antibody; and carrying out chemical coupling on the purified antibody and the fusion protein to obtain allergen specific IgE and IgG antibodies. By constructing allergen specific IgE and IgG antibodies, the kit can be simultaneously applied to detection of allergens IgE and IgG, has the advantages of high titer, high purity, good dilution linearity and the like, and is beneficial to improvement of diagnosis accuracy and treatment effectiveness.

A method for purifying a protein comprising an antibody, antibody fragment, or immunoglobulin single variable domain, from a solution containing at least one contaminant by superantigen chromatography comprising: a) adsorbing the protein to the superantigen immobilized on a solid support; b) removing the at least one contaminant by contacting the immobilized superantigen containing the adsorbed protein with a first wash buffer comprising an aliphatic carboxylate; and c) eluting the protein from the superantigen immobilized on the solid support.

In particular, the present invention provides techniques involving immune cells and antibody-recruiting molecules. In some embodiments, the immune cells are memory-like natural killer cells. In some embodiments, the provided techniques are particularly useful for conditions, disorders, or diseases such as cancer. In some embodiments, the provided techniques provide high efficacy. In some embodiments, the provided techniques provide fewer or less severe side effects associated with natural killer cell therapy.

The invention relates to the technical field of biology, in particular to a chicken CKAP4 protein polyclonal antibody and application and a kit thereof. An animal is immunized with the CKAP4 recombinant protein, serum is purified from the immunized animal, the chicken CKAP4 protein polyclonal antibody is obtained, and the amino acid sequence of the CKAP4 recombinant protein is shown as SEQ ID No.1. Sensitivity and specificity detection tests on the chicken CKAP4 protein polyclonal antibody find that the serum titer of CKAP4 is 1: 102400, the expression of the CKAP4 protein mainly focuses on cytoplasm parts of various organs of animals, and the polyclonal antibody can specifically bind to the CKAP4 protein in animal tissues. Therefore, the polyclonal antibody has the advantages of high sensitivity, good specificity, wide application range and the like, and a foundation is laid for later detection of CKAP4 protein and research on pathological mechanisms of virus infection diseases.

In various embodiments, the present invention provides a process for separating target proteins from non-target proteins in a sample comprising increasing the concentration of the target proteins and non-target proteins in the sample and subsequently delivering the concentrated sample to a chromatography device. In other embodiments, the invention relates to a process for increasing the capacity of a chromatography device for a target protein by delivering a concentrated sample comprising the target protein to a chromatography device.

The invention provides a portunus trituberculatus SCP antigen, antibody, kit and application, and belongs to the technical field of allergen detection. The antigen of the portunus trituberculatus SCP comprises an antigen epitope peptide of the portunus trituberculatus SCP and a carrier protein, and the amino acid sequence of the antigen epitope peptide of the portunus trituberculatus SCP is as shown in SEQ ID NO. 14. The antigen epitope peptide of the antigen portunus trituberculatus SCP has a relatively stable structure before and after thermal processing, the detection limit of an antibody prepared from the antigen for detecting a crustacean allergen is 0.32 mu g / mL, the quantitation limit is 1.06 mu g / mL, the crustacean allergen can be specifically detected, and the antibody can be used for detecting the crustacean allergen. In addition, when the antibody is used for detecting the crustacean allergen, the accuracy is good, the matrix interference resistance and the precision are high, and the high detection effect on the crustacean allergen in food processed at high temperature can still be kept.

Disclosed herein are improved methods for quantifying monoclonal antibody (mAb) titer using Protein A affinity High-Performance Liquid Chromatography (HPLC). The methods address inaccuracies caused by mAb adsorption to sample vial surfaces by incorporating a surfactant into the mobile phase used for sample dilution. This approach enhances the accuracy, linearity, and robustness of the titer assay, making it suitable for process control and quality assessment in biopharmaceutical development and manufacturing. The methods can be applied as a platform approach for various mAb products.

The invention provides an anti-grouper PSMB8 protein polyclonal antibody as well as a preparation method and application thereof. The anti-grouper PSMB8 protein polyclonal antibody is obtained by taking recombinant protein EcPSMB8 as an antigen immune animal, and the amino acid sequence of the recombinant protein EcPSMB8 is as shown in SEQ ID NO: 1. The polyclonal antibody for resisting the grouper PSMB8 protein, provided by the invention, has high specificity on the grouper PSMB8 protein, the problem that a high-specificity antibody for the grouper PSMB8 protein is lacked in the prior art is solved, and the grouper PSMB8 protein can be better and more effectively researched.

Provided is an anti-claudin-6 (CLDN6) antibody or an antigen-binding fragment thereof, including a chimeric monoclonal antibody and a humanized monoclonal antibody. This application further provides a nucleic acid encoding the anti-CLDN6 antibody, an expression vector and a host cell for expressing the anti-CLDN6 antibody, a conjugate, a multispecific antibody, a chimeric antigen receptor (CAR), and a pharmaceutical composition including the anti-CLDN6 antibody, and a method for verifying a function and efficacy of the anti-CLDN6 antibody. The anti-CLDN6 antibody of this application can be used for diagnosing a cancer and / or determining whether a cancer cell expresses CLDN6, and can also be used for treating and / or preventing various cancers or diseases associated with CLDN6-expressing cells in a subject.

The invention provides a preparation method and application of a polyclonal antibody for recognizing IL-33 protein K6 site lactic acid modification, and belongs to the technical field of biological medicine, the invention discloses that lactic acid modification of IL-33 protein 6th lysine (Lys6) plays a key role in occurrence and development of liver cancer, and experiments prove that the site lactic acid promotes liver cancer cell proliferation and tumor growth; based on the discovery, the invention innovatively proposes that Lys6 lactic acid is used as a new target for tumor diagnosis and treatment, and successfully develops an antigen peptide and an antibody tool for specifically recognizing the modification site; the preclinical invention shows that the progress of the liver cancer can be effectively inhibited by blocking the Lys6 lactylation, the constructed detection system shows high sensitivity and specificity in liver cancer diagnosis, and the developed targeted antibody drug also has remarkable anti-tumor activity.

The invention discloses a nano antibody for resisting a novel coronavirus mutant strain RBD structural domain antigen. The amino acid full-length sequence of the nano antibody is shown as any one of SEQ ID NO.5-8. The nano antibody disclosed by the invention has good capability of blocking the combination of a novel coronavirus mutant strain RBD and a receptor thereof, and can effectively prevent cells from being infected by viruses through experimental verification.

Described herein are anchor-modified immunoglobulin polypeptides, wherein the anchor moors the immunoglobulin polypeptide to a receptor of interest. The anchor-modified immunoglobulin polypeptides are generally characterized at the N-terminus with an anchor, e.g., the receptor binding portion of a ligand that binds a receptor. Non-human animals genetically modified with recombinant immunoglobulin segments that encode the anchor-modified immunoglobulin polypeptides are capable of making the anchor-modified immunoglobulin polypeptides. Such non-human animals also provided, along with methods and compositions for making and using the non-human animals. Methods for producing anchor-modified immunoglobulins from non-human animals are also provided, as well as anchor-modified immunoglobulins generated therefrom.

Described herein are anchor-modified immunoglobulin polypeptides, wherein the anchor moors the immunoglobulin polypeptide to a receptor of interest. The anchor-modified immunoglobulin polypeptides are generally characterized at the N-terminus with an anchor, e.g., the receptor binding portion of a ligand that binds a receptor. Non-human animals genetically modified with recombinant immunoglobulin segments that encode the anchor-modified immunoglobulin polypeptides are capable of making the anchor-modified immunoglobulin polypeptides. Such non-human animals also provided, along with methods and compositions for making and using the non-human animals. Methods for producing anchor-modified immunoglobulins from non-human animals are also provided, as well as anchor-modified immunoglobulins generated therefrom.

The present invention relates to a novel affinity ligand that binds to a single chain antibody fragment (scFv) that is specific for serum albumin. The novel affinity ligands of the present invention are powerful tools because they allow efficient purification methods for fusion proteins comprising scFv via affinity chromatography.

The present invention provides novel methods for reducing the serine protease and / or serine protease zymogen content of a plasma-derived protein composition. Also provided are methods for manufacturing plasma-derived protein compositions having reduced serine protease and / or serine protease zymogen content. Among yet other aspects, the present invention provides aqueous and lyophilized compositions of plasma-derived proteins having reduced serine protease and / or serine protease zymogen content. Yet other aspects include methods for treating, managing, and / or preventing a disease comprising the administration of a plasma-derived protein composition having a reduced serine protease or serine protease zymogen content.

The invention discloses a method for extracting immune globulin in fresh pig blood, and relates to the technical field of fresh pig blood extraction.The method comprises the following steps that firstly, a sample is pretreated, secondly, immune globulin is captured, Protein A / G or an antibody is fixed to the inner wall of a channel in a micro-fluidic chip, and the immune globulin is captured; 3, impurity flushing, wherein the channel is flushed through multi-stage cleaning; 4, immunoglobulin elution and collection, in the method, a micro-fluidic chip mode is adopted, and the immunoglobulin extraction speed can be increased; in the micro-fluidic chip, Protein A / G or an antibody is fixed on the inner wall of a channel to capture the immune globulin, and then the immune globulin is eluted from the channel and collected, so that the extraction speed of the immune globulin is increased; the channel is flushed through multi-stage cleaning, so that the extraction purity of immune globulin can be improved; the immune globulin capturing efficiency is improved through the tuning algorithm, and the concentration of the captured immune globulin is improved.

The application belongs to the technical field of biotechnology, and particularly relates to a human metapneumovirus mouse-adapted strain and application thereof. Compared with wild strains, the strain can exhibit stronger susceptibility to animals, and can cause typical clinical symptoms and even death. For example, after the strain infects BALB / c mice, the disease symptoms are obvious, 83% of the mice have a severe decrease in body weight to below 75% after infection, and have reached the humane killing standard. Four days after the strain infects BALB / c mice, the mortality rate is above 50%. The strain can be used to construct a cell model or an animal model of human metapneumovirus infection or a disease caused by the human metapneumovirus, and is further used to screen drugs for preventing and / or treating human metapneumovirus infection or a disease caused by the human metapneumovirus. In addition, the strain can also be used to prepare drugs for preventing and / or treating human metapneumovirus infection or a disease caused by the human metapneumovirus, and to prepare antibodies or antisera against the human metapneumovirus.